Detail of "123663-49-0"

CAS Number:
123663-49-0
Name:
Methanesulfonamide,N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-
Superlist Name:
Iguratimod
Molecular Structure:
Formula:
C₁₇H₁₄N₂O₆S
Molecular Weight:
374.37
Synonyms:
T 614;T614 (antiinflammatory);Ailamode;3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one;N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl]methanesulfonamide;
Density:
1.52 g/cm³
Boiling Point:
580.6 °C at 760 mmHg
Flash Point:
304.9 °C
Appearance:
white powder

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Supplier Location
Supplier Location
- China (Mainland)(19)
Business Type
Business Type
- Lab/Research institutions(3)
- Manufacturers(1)
- Trading Company(11)
Certificates
Certificates
- ISO(1)
- Production License (0)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice: All Rights Reserved. Some chemicals with cas registry numbers like 123663-49-0 are also used. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice. Tanaka, K.; Urata, N.; Mikami, M.; Ogasawara, M.; Matsunaga, T.; Terashima, N.; Suzuki, H. (Research Laboratories, Toyama Chemical Co., Ltd., Shimookui 2-4-1, Toyama 930-8508, Japan). Inflammation Research, Volume Date 2007, 56(1), 17-23 (English) 2006 Birkhaeuser Verlag. CODEN: INREFB. ISSN: 1023-3830. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 14 The study examd. the effect of iguratimod (T-614) and other anti-rheumatic drugs on a mouse model of adenocarcinoma-induced cachexia. Cachexia was induced in BALB/c mice by s.c. inoculation of colon 26/clone 20 cells (day 0). The drugs were administered p.o. daily from day 0 for 15 days for prophylactic expts. and from day 7 for 8 days for therapeutic expts. Serum biochem. parameters and wasting of adipose tissue and muscle were evaluated as the nutritional condition in tumor-bearing mice at day 14. Interleukin-6 (IL-6) levels in serum and tumor tissue of those mice were also quantified. Administration of T-614 did not inhibit the tumor growth, but it resulted in attenuation of cachexia symptoms, such as the redn. in epididymal fat and gastrocnemius muscle, and the decrease of serum albumin. Furthermore, T-614 decreased the serum levels of IL-6, and reduced its gene expression in the tumor tissues. Exogenously administered IL-6 nullified the suppressive effect of T-614. Prednisolone prevented the wt. loss and the wasting without inhibiting tumor growth. Methotrexate and indomethacin did not exert any preferable effects in a therapeutic dosing schedule. Our results demonstrate that T-614 exerts an anticachectic effect in tumor-bearing mice through the inhibition of IL-6 gene expression. .

Detail of "123663-49-0"

Methanesulfonamide,N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

CAS No.123663-49-0 Iguratimod

Reference